Osteoporosis: Diagnosis, Prevention & Evidence-Based Treatment
Medically reviewed by Medical Advisory Board Last reviewed 2026-08-12
When bone density drops below the fracture threshold — causes, testing, and what actually works
Osteoporosis affects 10 million Americans and causes 2 million fractures annually. It is defined by a DEXA T-score below -2.5 and represents significant skeletal fragility. Early diagnosis and treatment can reduce fracture risk by 40-70%.
Osteoporosis is a skeletal disorder characterized by reduced bone mass and microarchitectural deterioration, leading to increased bone fragility and fracture susceptibility. It is diagnosed when a DEXA scan reveals a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip — or when a fragility fracture occurs regardless of T-score.
The clinical significance of osteoporosis lies in its fractures. Hip fractures carry a 20-30% one-year mortality rate in adults over 65. Vertebral compression fractures cause chronic pain, height loss, and kyphosis. Wrist fractures, often the first osteoporotic fracture, are a warning signal for future hip and spine fractures.
Want expert help with your hormone health?
We can match you with a board-certified hormone specialist who understands this area — so you get the right doctor, not just any doctor.
Book An Appointment With A Specialist →Despite effective treatments that reduce fracture risk by 40-70%, osteoporosis remains dramatically undertreated. Only 20-25% of women who sustain an osteoporotic fracture receive appropriate evaluation or treatment afterward.
Diagnosis and Risk Assessment
DEXA scan: Measures bone mineral density at the spine, hip, and sometimes forearm. T-score below -2.5 at any site confirms osteoporosis.
FRAX score: The WHO Fracture Risk Assessment Tool calculates 10-year probability of major osteoporotic fracture and hip fracture using clinical risk factors. Treatment is generally recommended when 10-year hip fracture risk exceeds 3% or major osteoporotic fracture risk exceeds 20%.
Secondary causes to evaluate: Vitamin D deficiency, hyperparathyroidism, hyperthyroidism, celiac disease, multiple myeloma, Cushing's syndrome, hypogonadism, and medication-induced bone loss (corticosteroids, aromatase inhibitors, anticonvulsants).
Treatment Options
First-line pharmacological therapy:
- Bisphosphonates (alendronate, risedronate, zoledronic acid): Reduce fracture risk by 40-50%. Work by inhibiting osteoclast-mediated bone resorption. Oral (weekly) or IV (yearly). Treatment duration: typically 5 years oral, 3 years IV, then reassess.
- Denosumab (Prolia): Monoclonal antibody targeting RANKL. Reduces hip fracture risk by 40%, vertebral by 68%. Given as subcutaneous injection every 6 months. Discontinuation causes rapid bone loss — transition plan required.
Anabolic agents (bone-building):
- Romosozumab (Evenity): Anti-sclerostin antibody that both builds bone and reduces resorption. Increases spine BMD by 13% and hip by 7% over 12 months. Reserved for very high fracture risk. 12-month treatment followed by antiresorptive therapy.
- Teriparatide (Forteo): PTH analog that stimulates osteoblasts. Increases spine BMD by 9-13% over 18-24 months. Maximum 2-year treatment course.
Not sure which of these fits your situation? See our osteoporosis medications compared guide for a full side-by-side on dosing schedule, fracture-site strength, kidney function, and side effects.
Lifestyle Interventions
- Exercise: Resistance training and weight-bearing impact exercise remain essential even with pharmacological treatment. Fall prevention (balance training, tai chi) reduces fracture risk by preventing falls, which is equally important as improving bone density.
- Nutrition: Calcium 1,200 mg/day, vitamin D to maintain 25(OH)D above 40 ng/mL, protein 1.0-1.2 g/kg/day. Vitamin K2 (MK-7, 100-200 mcg/day) may improve calcium deposition into bone rather than soft tissues.
- Fall prevention: Home safety assessment (rugs, lighting, grab bars), vision correction, medication review (sedatives, antihypertensives that cause dizziness), and balance exercises reduce fall risk by 30-40%.
Practical guides: DEXA scan and diagnosis, T-score and Z-score, bone-building exercise, calcium-rich foods, earlier-stage osteopenia, and menopause-related bone loss.
Does Menopause Cause Osteoporosis? HRT and Bone Density Explained
Menopause does not directly cause osteoporosis in every woman who goes through it — it is more accurately described as the single largest risk factor for osteoporosis in women, acting through estrogen decline rather than as a guaranteed, automatic outcome. Many women who prioritize exercise, nutrition, and other modifiable risk factors never cross the osteoporosis threshold, while a smaller number of premenopausal women develop osteoporosis from unrelated causes (glucocorticoid use, hyperparathyroidism, and other secondary causes covered above) with no connection to menopause at all. The distinction matters clinically: osteoporosis is diagnosed by a DEXA T-score or a fragility fracture, not by menopausal status alone, and the interventions that lower risk — including hormone therapy — work specifically on the estrogen-decline mechanism that menopause introduces, not on menopause as an event in itself.
Hormone therapy (HRT) and bone density: Estrogen therapy or combined hormone therapy is well established to preserve bone density and reduce fracture risk when started during the menopause transition — generally within about 10 years of a woman's final period or before age 60, in women without contraindications. The Women's Health Initiative (WHI) found that estrogen-containing hormone therapy reduced hip fractures by roughly a third and vertebral fractures by a similar margin, and bone protection is now considered one of several legitimate benefits of hormone therapy for appropriate candidates being treated primarily for menopausal symptoms — not, by itself, a reason to start HRT in women without symptoms or other indications. Because this fracture-prevention effect fades once treatment stops, HRT is best understood as protective for as long as it's taken during the highest-risk window rather than as a treatment that leaves a lasting effect once discontinued.
For women who cannot or choose not to use hormone therapy, the same bone-protective goal can be pursued through the exercise, nutrition, and non-hormonal medication options covered throughout this page. See bone density and menopause for the full mechanism and timeline of estrogen-related bone loss.
What Makes a Good Bone-Support Supplement
Get calcium from food first; if you supplement, calcium citrate absorbs better than carbonate and is gentler without a meal. Keep total calcium (food + pills) around 1,000–1,200 mg/day — more doesn't help bone. Pair it with vitamin D3 and K2, which help calcium reach bone, and split doses to ~500 mg for better absorption.
Frequently Asked Questions
Can osteoporosis be reversed?
Osteoporosis can be significantly improved with modern treatments. Anabolic agents like romosozumab can increase spine bone density by 13% in 12 months, and teriparatide by 9-13% over 2 years. Bisphosphonates and denosumab prevent further loss and modestly increase density. While complete reversal to normal T-scores is uncommon, reducing fracture risk by 40-70% with treatment is well established.
What are the 3 worst bone density drugs?
This question typically refers to concerns about bisphosphonate side effects. The rare but serious risks include: (1) atypical femur fractures (risk: ~1 in 10,000 per year, mainly with use beyond 5 years), (2) osteonecrosis of the jaw (risk: ~1 in 10,000-100,000 for oral bisphosphonates, higher with IV formulations in cancer patients), and (3) esophageal irritation with oral bisphosphonates. However, for most patients the fracture-prevention benefit far outweighs these risks. Drug holidays after 5 years of oral or 3 years of IV bisphosphonates mitigate long-term risks.
Can osteoporosis be reversed to osteopenia?
Yes, this is achievable with treatment. Anabolic agents (romosozumab, teriparatide) can increase bone density enough to shift T-scores from the osteoporosis range into osteopenia. Even antiresorptive treatments (bisphosphonates, denosumab) can achieve this, particularly at the lumbar spine. The goal of treatment is primarily fracture prevention, but T-score improvement is a measurable outcome.
How to prevent osteoporosis after menopause?
Prevention starts during the accelerated bone loss phase (first 5-7 years postmenopause): (1) progressive resistance training 2-3x/week with impact exercises, (2) calcium 1,200 mg/day from food + supplements, (3) vitamin D 1,000-4,000 IU/day to maintain levels above 40 ng/mL, (4) adequate protein, (5) consider hormone therapy if appropriate (reduces fracture risk 30-40%), and (6) baseline DEXA scan within 2 years of menopause if risk factors are present.
Does menopause cause osteoporosis?
Menopause itself is the largest risk factor for osteoporosis in women, not a direct, automatic cause. The estrogen decline that occurs at menopause accelerates bone loss, and if that accelerated loss goes unaddressed for long enough, it can cross the T-score or fracture threshold that defines osteoporosis. But many women who address modifiable risk factors — exercise, calcium and vitamin D, and sometimes hormone therapy or medication — never develop osteoporosis despite going through menopause, which is why menopause is best understood as a major risk factor operating through estrogen decline rather than a disease-causing event on its own.
Does HRT help with bone density?
Yes. Estrogen-containing hormone therapy is well established to preserve bone density and reduce fracture risk, with the Women's Health Initiative finding roughly a third fewer hip fractures and a similar reduction in vertebral fractures among women on hormone therapy. The benefit is strongest when started during the menopause transition — generally within about 10 years of the final period or before age 60 — in women without contraindications, and it fades once treatment is stopped, so it's most useful as protection during the highest-risk window rather than a one-time fix.
Is osteoporosis treatment for life, or does it have an end point?
It depends on the drug class, not on the diagnosis itself. Oral bisphosphonates are typically used for about 5 years and IV zoledronic acid for about 3 years, after which many patients take a "drug holiday" since the drugs remain bound to bone and keep exerting some protective effect after stopping. Denosumab has no built-in holiday — stopping it requires transitioning to a bisphosphonate to prevent a rebound surge in bone loss. Anabolic drugs (teriparatide, romosozumab) are capped at 2 years and 12 months respectively by regulatory approval and are always followed by an antiresorptive. See our full osteoporosis medications comparison for how the schedules and tradeoffs differ by drug.
Can osteoporosis be treated without medication?
For some patients, yes — but it depends on FRAX-calculated fracture risk, not personal preference alone. Guidelines generally reserve a lifestyle-only approach (resistance training, calcium, vitamin D, fall prevention) for lower-risk cases, while pharmacological treatment is recommended once 10-year hip fracture probability exceeds 3% or major osteoporotic fracture probability exceeds 20% — the same FRAX thresholds used to decide whether osteopenia needs medication. A prior fragility fracture or a T-score below roughly -3.0 generally places someone in the treat-with-medication category regardless of how well lifestyle factors are otherwise controlled, because the near-term refracture risk is too high to rely on lifestyle alone. This is a conversation to have directly with your prescriber using your own FRAX score and fracture history, not a decision to make from a T-score in isolation.
Topic updates
Get the weekly hormone optimization roundup
Testosterone, thyroid, cortisol, estrogen, menopause, perimenopause, libido, and hormone testing.
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Reading
← Back to Hormone Optimization
-
Osteoporosis Medications Compared — Bisphosphonates, Denosumab, and Anabolic Agents
Osteoporosis medications compared: bisphosphonates vs denosumab vs anabolic agents.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.